Sabby Management LLC decreased its stake in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 223,100 shares of the biotechnology company’s stock after selling 15,807 shares during the quarter. Sabby Management LLC owned approximately 2.67% of Eiger BioPharmaceuticals worth $1,762,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Susquehanna International Group LLP purchased a new stake in Eiger BioPharmaceuticals in the second quarter worth about $114,000. Goldman Sachs Group Inc. purchased a new stake in Eiger BioPharmaceuticals in the second quarter worth about $272,000. Hikari Power Ltd increased its position in Eiger BioPharmaceuticals by 491.0% in the second quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after buying an additional 50,672 shares in the last quarter. Bank of New York Mellon Corp increased its position in Eiger BioPharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares in the last quarter. Finally, LMR Partners LLP purchased a new stake in Eiger BioPharmaceuticals in the second quarter worth about $116,000. Institutional investors and hedge funds own 59.94% of the company’s stock.

In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn purchased 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the purchase, the director now directly owns 31,355 shares in the company, valued at $298,813.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.80% of the stock is owned by insiders.

A number of analysts have commented on EIGR shares. Piper Jaffray Companies restated a “buy” rating and issued a $36.00 price target on shares of Eiger BioPharmaceuticals in a research report on Tuesday, August 15th. Wedbush restated an “outperform” rating and issued a $34.00 price target (up previously from $28.00) on shares of Eiger BioPharmaceuticals in a research report on Wednesday, June 21st. Zacks Investment Research cut Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $34.00 price target on shares of Eiger BioPharmaceuticals in a research report on Monday, September 25th. Finally, ValuEngine upgraded Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Eiger BioPharmaceuticals has a consensus rating of “Buy” and a consensus price target of $29.67.

Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ EIGR) traded down 0.42% during mid-day trading on Tuesday, reaching $11.80. The company’s stock had a trading volume of 16,999 shares. The firm’s market cap is $98.73 million. The firm’s 50-day moving average price is $10.97 and its 200 day moving average price is $8.70. Eiger BioPharmaceuticals, Inc. has a 12-month low of $6.10 and a 12-month high of $14.75.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.05). On average, analysts expect that Eiger BioPharmaceuticals, Inc. will post ($5.21) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/17/sabby-management-llc-has-1-76-million-holdings-in-eiger-biopharmaceuticals-inc-eigr.html.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Institutional Ownership by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.